BRAF and metastatic melanoma: Selumetinib plus docetaxel in previously treated patients with KRAS-mutant advanced non-small cell lung cancer (NSCLC) [12], and selumetinib plus dacarbazine in patients with BRAF-mutant metastatic melanoma [13], have more recently been assessed in phase II trials.